With our registration software and imaging processing algorithms, we were able to correlate individual druse sizes measured on CFP with those determined on SD-OCT. These data can be used to develop an SD-OCT-based grading scale, analogous to the CFP AREDS drusen scale, that may be useful in the clinic and in clinical trials.

With our registration software and imaging processing algorithms, we were able to correlate individual druse sizes measured on CFP with those determined on SD-OCT. These data can be used to develop an SD-OCT-based grading scale, analogous to the CFP AREDS drusen scale, that may be useful in the clinic and in clinical trials.

To evaluate 18 months’ results of a strict anti-VEGF protocol for radiation maculopathy (RM) following proton therapy in choroidal melanoma.

Retrospective, comparative, non-randomized study of 74 RM patients presenting macular lipid deposits, hemorrhages, microaneurysms, cystoid edema, nerve layer infarction, telangiectasia or capillary nonperfusion. The study group included 52 consecutive patients injected with intravitreal anti-VEGFs (bevacizumab/ranibizumab 46/6) every two months for the first and every three months for the second year, with minimum 12 months’ follow-up. The control group consisted of 22 patients having declined this treatment. BCVA, SD-OCT and OCTA were recorded at baseline, 6, 12 and 18 months. The foveal avascular zone (FAZ) and capillary density (CD) were measured at the superficial capillary plexus.

RM was diagnosed at 2 years [1.5-3.5] after proton therapy. BCVA at baseline, 12 and 18 months improved in the study group from 0.45, 0.3 to 0.2 LogMar, but decreased in the control group from 0.5, 0.9 to 1.0 LogMar respectively (p<0.001 at 12 months). find more Simultaneously, FAZ enlargement was less in the study (from 0.377, 0.665 to 0.744 mm2) than control group (from 0.436, 1.463 to 2.638 mm2) (p=0.05 at 12 months). CMT (280 and 276 µm) and CD (37 and 38%, at baseline, respectively) did not evolve significantly different.

Intravitreal anti-VEGFs, every two months for the first and every three months for the second year, slow down, over up to 18 months, vision loss and anatomical degradation in RM following proton therapy for choroidal melanoma.

Intravitreal anti-VEGFs, every two months for the first and every three months for the second year, slow down, over up to 18 months, vision loss and anatomical degradation in RM following proton therapy for choroidal melanoma.

To determine the incidence of complete resolution of choroidal neovascular membrane(CNV) associated exudation with a single anti-vascular endothelial growth factor(anti-VEGF) injection in treatment naïve wet age related macular degeneration(AMD) patients and its associated characteristics.

Retrospective, observational study of naïve wet AMD patients who received anti-VEGF therapy with ranibizumab/aflibercept and demonstrated complete resolution of retinal exudation with a single injection. Complete resolution was defined as total disappearance of the intraretinal fluid, cysts and subretinal fluid and a return of retinal thickness to <250 microns on spectral domain optical coherence tomography(SDOCT). All relevant data was collected. Follow up was scheduled on days 1, 7 and 30 postoperatively and then monthly, with at least 9 visits mandatory per year if the macula remained fluid free. Appropriate statistical analyses were performed.

63 patients(29 males; mean age 67.25±4.40 years) were identified. The mean baseline and final corrected distance visual acuity(CDVA) was 20/160 and 20/45 respectively. Patients completed a mean of 10.9 follow-up visits per year. Smaller CNVs(<200 microns), early presentation, better presenting CDVA, sub-foveal CNVs, absence of blood/fibrosis and use of aflibercept(2mg) favoured resolution with one injection.

A subset(13.76%; 63/458,95% confidence intervals 10.73-17.25) of patients with treatment naïve wet AMD demonstrates resolution of CNV associated exudation with a single anti-VEGF injection, sustained over 2 years or more. This can lower therapy costs, treatments, office visits and the potential risk of geographic atrophy.

A subset(13.76%; 63/458,95% confidence intervals 10.73-17.25) of patients with treatment naïve wet AMD demonstrates resolution of CNV associated exudation with a single anti-VEGF injection, sustained over 2 years or more. This can lower therapy costs, treatments, office visits and the potential risk of geographic atrophy.

To describe a novel method of subretinal injection to reduce the risk of foveal dehiscence during subretinal tissue plasminogen activator (TPA) delivery for submacular haemorrhage.

Description of technique with illustrative case description and details of four cases treated. The subretinal injection is delivered under a perfluorocarbon liquid (PFCL) bubble filling 80% of the vitreous cavity. An eccentric injection point is used and the TPA injected under pneumatically controlled viscous fluid injection system with a 38g polyimide cannula and low injection pressure.

Four cases have been treated with controlled subretinal injection extending under the fovea without dehiscence, including one case with apparent pre-existing foveal dehiscence and a pre retinal clot.

The technique allows the creation of a low more diffuse subretinal bleb compared to without PFCL, minimising hydraulic stress on the fovea during injection and could be applied to other subretinal injection scenarios where the fovea is at risk of hydraulic blow out. Further experience of the technique is needed to validate this initial report.

The technique allows the creation of a low more diffuse subretinal bleb compared to without PFCL, minimising hydraulic stress on the fovea during injection and could be applied to other subretinal injection scenarios where the fovea is at risk of hydraulic blow out. Further experience of the technique is needed to validate this initial report.

To highlight the challenge of correct reproductive and therapeutic counselling in complex pedigrees with different inherited retinal dystrophies.

208 patients diagnosed with non-syndromic inherited retinal dystrophies underwent full ophthalmologic examination and molecular analysis using targeted next-generation sequencing.

Five families (4%) carried mutations in more than one gene that contribute to different inherited retinal dystrophies. Family fRPN-NB had a dominant mutation in SNRNP200, which was present in nine affected individuals and four unaffected, and a mutation in RP2 among 11 family members. Family fRPN-142 carried a mutation in RPGR that cosegregated with the disease in all affected individuals. Additionally, the proband also harbored two disease causing-mutations in the genes BEST1 and SNRNP200. Family fRPN-169 beared compound heterozygous mutations in USH2A and a dominant mutation in RP1. Genetic testing of fRPN-194 determined compound heterozygous mutations in CNGB3 and a dominant mutation in PRPF8 only in the proband.